Bos

utin

ib

AM

PK

Inhi

bito

r, C

ompo

und

C

Sun

itini

b

Dov

itini

b

Syk

Inhi

bito

r

GS

K−3

Inhi

bito

r IX

Sta

uros

porin

e, N

−ben

zoyl

−

SU

1165

2

Indi

rubi

n D

eriv

ativ

e E

804

SB

218

078

Sta

uros

porin

e, S

trept

omyc

es s

p.

K−2

52a,

Noc

ardi

opsi

s sp

.

Cdk

1/2

Inhi

bito

r III

Gˆ 6

976

PK

R In

hibi

tor

JAK

3 In

hibi

tor V

I

JAK

Inhi

bito

r I

Isog

ranu

latim

ide

Met

Kin

ase

Inhi

bito

r

IKK

−2 In

hibi

tor I

V

VE

GF

Rec

epto

r 2 K

inas

e In

hibi

tor I

II

Auro

ra K

inas

e/C

dk In

hibi

tor

Als

terp

aullo

ne, 2

−Cya

noet

hyl

Cdk

4 In

hibi

tor

Als

terp

aullo

ne

SU

9516

Am

inop

urva

lano

l A

GS

K−3

Inhi

bito

r X

Flt−

3 In

hibi

tor I

I

Indi

rubi

n−3?

−mon

oxim

e

GS

K−3

Inhi

bito

r XIII

Cdk

2 In

hibi

tor I

V, N

U61

40

SU

6656

GS

K3b

Inhi

bito

r XII,

TW

S11

9

Das

atin

ib

Vand

etan

ib

Lck

Inhi

bito

r

Toza

serti

b

PD

GF

RTK

Inhi

bito

r

Pazo

pani

b

Ro−

32−0

432

Bis

indo

lylm

alei

mid

e IV

PK

Cb

Inhi

bito

r

Bis

indo

lylm

alei

mid

e I

Go

6983

JNK

Inhi

bito

r II

PK

R In

hibi

tor,

Neg

ativ

e C

ontro

l

Alo

isin

e A

, RP

107

Alo

isin

e, R

P10

6

Pur

vala

nol A

Com

poun

d 52

Cdk

1 In

hibi

tor,

CG

P74

514A

Nilo

tinib

PD

GF

Rec

epto

r Tyr

osin

e K

inas

e In

hibi

tor I

V

Sor

afen

ib

PD

K1/

Akt

/Flt

Dua

l Pat

hway

Inhi

bito

r

Syk

Inhi

bito

r II

VE

GF

Rec

epto

r 2 K

inas

e In

hibi

tor I

I

VE

GF

Rec

epto

r 2 K

inas

e In

hibi

tor I

Flt−

3 In

hibi

tor I

II

VE

GF

Rec

epto

r 2 K

inas

e In

hibi

tor I

V

PP

1 A

nalo

g II,

1N

M−P

P1

JAK

3 In

hibi

tor I

I

Src

Kin

ase

Inhi

bito

r I

BP

IQ−I

AG 1

478

Com

poun

d 56

EG

FR/E

rbB

−2/E

rbB

−4 In

hibi

tor

EG

FR/E

rbB

−2 In

hibi

tor

PD

158

780

Erlo

tinib

Gef

itini

b

Kenp

aullo

ne

Cdk

/Crk

Inhi

bito

r

JNK

Inhi

bito

r V

STO

−609

Cas

ein

Kin

ase

II In

hibi

tor I

II, T

BC

A

Cdc

2−Li

ke K

inas

e In

hibi

tor,

TG00

3

p38

MA

P K

inas

e In

hibi

tor I

II

PD

169

316

p38

MA

P K

inas

e In

hibi

tor

SK

F−86

002

SB

2200

25

SB

202

190

SB

203

580

GS

K−3

b In

hibi

tor X

I

H−8

9, D

ihyd

roch

lorid

e

HA

107

7, D

ihyd

roch

lorid

e, F

asud

il

GTP

−145

64

IRA

K−1

/4 In

hibi

tor

Flt−

3 In

hibi

tor

DM

BI

VE

GF

Rec

epto

r Tyr

osin

e K

inas

e In

hibi

tor I

II, K

RN

633

VE

GF

Rec

epto

r Tyr

osin

e K

inas

e In

hibi

tor I

I

Mas

itini

b

Imat

inib

PD

GF

Rec

epto

r Tyr

osin

e K

inas

e In

hibi

tor I

II

Vata

lani

b

AGL

2043

Tand

utin

ib

PI 3

−Kg

Inhi

bito

r

PI 3

−Kg

Inhi

bito

r II

Tpl2

Kin

ase

Inhi

bito

r

PD

174

265

Lapa

tinib

JNK

Inhi

bito

r, N

egat

ive

Con

trol

Rho

Kin

ase

Inhi

bito

r III,

Roc

kout

RO

CK

Inhi

bito

r, Y

−276

32

Rho

Kin

ase

Inhi

bito

r IV

Ros

covi

tine

Cdk

2 In

hibi

tor I

II

Boh

emin

e

VX

−702

MN

K1

Inhi

bito

r

ER

K In

hibi

tor I

I, FR

1802

04

TGF−

b R

I Kin

ase

Inhi

bito

r

TGF−

b R

I Inh

ibito

r III

SC

−683

76

IC26

1

Cas

ein

Kin

ase

I Inh

ibito

r, D

4476

Auro

ra K

inas

e In

hibi

tor I

II

Tofa

citin

ib

Wor

tman

nin

Fasc

aply

sin,

Syn

thet

ic

AG 1

296

AG 1

295

Chk

2 In

hibi

tor I

I

Cdk

4 In

hibi

tor I

II

Cdk

4 In

hibi

tor I

I, N

SC

625

987

Che

lery

thrin

e C

hlor

ide

Cdk

1/5

Inhi

bito

r

Cdk

1 In

hibi

tor

cFM

S R

ecep

tor T

yros

ine

Kin

ase

Inhi

bito

r

PK

CbI

I/EG

FR In

hibi

tor

PD

GF

Rec

epto

r Tyr

osin

e K

inas

e In

hibi

tor I

I

PI−

103

PP

3

PD

980

59

LY 2

9400

2

JNK

Inhi

bito

r VIII

JNK

Inhi

bito

r IX

NF−

kB A

ctiv

atio

n In

hibi

tor

KN

−62

KN

−93

LY 3

0351

1− N

egat

ive

cont

rol

MK

2a In

hibi

tor

ME

K1/

2 In

hibi

tor

JAK

3 In

hibi

tor I

V

ME

K In

hibi

tor I

ME

K In

hibi

tor I

I

AG 1

024

GS

K−3

b In

hibi

tor V

III

GS

K−3

b In

hibi

tor I

I

AG 1

12

Syk

Inhi

bito

r III

AG 9

AG 4

90

Mub

ritin

ib

SB

202

474,

Neg

ativ

e co

ntro

l for

p38

MA

PK

Sph

ingo

sine

Kin

ase

Inhi

bito

r

Rap

amyc

in

EG

FR In

hibi

tor

DN

A−P

K In

hibi

tor I

I

IGF−

1R In

hibi

tor I

I

Her

bim

ycin

A, S

trept

omyc

es s

p.

GS

K−3

b In

hibi

tor I

ER

K In

hibi

tor I

II

DN

A−P

K In

hibi

tor V

DN

A−P

K In

hibi

tor I

II

Dia

cylg

lyce

rol K

inas

e In

hibi

tor I

I

ATM

Kin

ase

Inhi

bito

r

Akt

Inhi

bito

r X

Bcr

−abl

Inhi

bito

r

BAY

11−

7082

Akt

Inhi

bito

r V, T

riciri

bine

ATM

/ATR

Kin

ase

Inhi

bito

r

Akt

Inhi

bito

r IV

Akt

Inhi

bito

r VIII

, Iso

zym

e−S

elec

tive,

Akt

i−1/

2

RIPK2BRKLIMK1SIK2BMX/ETKBTKTXKPDGFRaABL1LYN BEPHA6c−KitFMSPDGFRbBLKLCKHCKABL2/ARGLYNc−SRCFYNACK1YES/YES1FGRLOK/STK10FLT4/VEGFR3KHS MAP4K5RETHGK MAP4K4FLT3TRKCAurora BTRKBMLK1/MAP3K9ARK5/NUAK1MLK3/MAP3K11MLCK2/MYLK2LRRK2TRKARSK3RSK4RSK1RSK2Aurora ATYK2CHK2MELKMARK4MINK/MINK1GCK MAP4K2PHKg1MST1/STK4MST2/STK3GSK3aGSK3bCDK9/cyclin T1CDK9 cyclin KCDK6/cyclin D1CDK6/cyclin D3CDK1/cyclin BCDK2/cyclin ECDK5/p25CDK2/cyclin ACDK5/p35SLK/STK2FGFR1FLT1/VEGFR1KDR/VEGFR2CLK4CLK2ULK3MYO3bMST3/STK24PKN1/PRK1FERAurora CJAK3STK22D/TSSK1TAOK3/JIKDRAK1/STK17ABRSK1BRSK2PKCnu/PRKD3PKD2/PRKD2PKCmu/PRKD1STK33CAMKK2CAMK2dCAMK2aCHK1TBK1TAK1MARK2/PAR−1BaMARK3MARK1MNK2HaspinMUSKCLK1DYRK1BDYRK1/DYRK1APIM3PIM1MLCK/MYLKPKG2/PRKG2p70S6K/RPS6KB1MSK2/RPS6KA4MSK1/RPS6KA5LKB1STK16IRR/INSRRFAK/PTK2ITKCAMK2gSGK1CAMK2bROS/ROS1SYKSNARK/NUAK2MLK2/MAP3K10MEKK2MEKK3JAK2JAK1ULK1c−MERFGFR3TYK1/LTKPYK2ALKIRAK4IRAK1IKKe/IKBKECAMKK1CK2a2DYRK2TLK2CDK3/cyclin ECDK1/cyclin ACDK4/cyclin D1CDK4/cyclin D3MST4PKCaPKCdPKCgPKCthetaPKCetaPKCepsilonPKCb2PKCb1CK1epsilonCK1dFGFR2AXLTYRO3 SKYROCK2FES/FPSULK2NEK1TAOK1TAOK2/TAO1EGFRERBB4/HER4FRK/PTK5CSKEPHB4EPHB1ZAK/MLTKDDR2EPHB3EPHA3EPHA8EPHA1EPHA2EPHB2EPHA4EPHA5STK38/NDR1PKAcgPHKg2GRK6GRK7PKG1aPKN2/PRK2PDK1/PDPK1PKG1bPRKXROCK1PAK1STK25/YSK1EPHA7PAK5IGF1RMNK1IRDAPK1ZIPK/DAPK3TTKNEK4NEK9SGK2PASKMKK6DYRK3MEK2MEK1CAMK1dPBK/TOPKPKAAKT3p70S6Kb/RPS6KB2PAK2PAK3PAK4CAMK1aRIPK5ASK1/MAP3K5CLK3CK2aCK1a1NLKERBB2/HER2SRMSTECP38a/MAPK14P38b/MAPK11BRAFRAF1ARAFJNK2CK1g1CK1g3CK1g2MSSK1/STK23SRPK2CDK7/cyclin HTGFBR2PIM2DAPK2PLK3PLK1c−METFGFR4TIE2/TEKWEE1HIPK3HIPK4HIPK2SRPK1STK39/STLK3MRCKa/CDC42BPAIKKb/IKBKBDCAMKL2MAPKAPK5/PRAKIKKa/CHUKPAK6TSSK2ZAP70GRK4CAMK1gCAMK1bPKCiotaMRCKb/CDC42BPBMAPKAPK2PKCzetaAKT2AKT1SGK3/SGKLGRK5ALK1/ACVRL1ERK1JNK1ERK2 MAPK1VRK1WNK3NEK3NIK/MAP3K14NEK2NEK11ALK2/ACVR1RON/MST1ROSR1/OXSR1DMPKMAPKAPK3CAMK4GRK3GRK2PLK2CTK MATKJNK3COT1/MAP3K8DYRK4NEK7P38gHIPK1NEK6P38d/MAPK13WNK2ALK5/TGFBR1ALK4/ACVR1B